WHAT IS CLAIMED IS:

1. Use of an IL-17 antibody in the preparation of a medicament for treating psoriasis, wherein the IL-17 antibody is:

a) adapted for administration to a patient in need thereof during an induction regimen, wherein the induction regimen comprises a loading regimen, wherein the loading regimen comprises five doses of 150 mg - 300 mg of the IL-17 antibody, each of the five doses adapted for delivery weekly, beginning on week zero; and

b) thereafter, adapted for administration to the patient during a maintenance regimen, wherein said IL-17 antibody binds to an epitope of an IL-17 homodimer having two mature IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain, wherein the IL-17 antibody has a K_D of 100-200 pM, and wherein the IL-17 antibody has an *in vivo* half-life of 23-30 days.

2. The use according to claim 1, wherein the loading regimen comprises five doses of 150 mg or 300 mg of the IL-17 antibody.

3. The use according to claim 2, wherein the five doses of 150 mg are indicated for administration to the patient if the patient weighs less than 90 kg and wherein the five doses of 300 mg are indicated for administration to the patient if the patient weighs more than or equal to 90 kg.

4. The use according to claim 3, wherein the induction regimen further comprises a dose of 150 mg - 300 mg of the IL-17 antibody during week eight.

5. The use according to any one of claims 1-4, wherein the maintenance regimen comprises a monthly dose of 150 mg - 300 mg of the IL-17 antibody.

6. The use according to any one of claims 1-4, wherein the maintenance regimen comprises at least one dose of 150 mg - 300 mg of the IL-17 antibody at start of relapse.

7. The use according to claim 6, wherein the maintenance regimen further comprises at least one dose of 150 mg - 300 mg of the IL-17 antibody at each additional start of relapse.

8. Use of an IL-17 antibody in the preparation of a medicament for treating psoriasis, wherein at least one dose of the IL-17 antibody is adapted for administration to a patient in need thereof at start of relapse from a prior treatment with the IL-17 antibody, wherein said IL-17 antibody binds to an epitope of an IL-17 homodimer having two mature IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain, wherein the IL-17 antibody has a K_D of 100-200 pM, and wherein the IL-17 antibody has an *in vivo* half-life of 23-30 days..

9. The use according to claim 8, wherein the at least one dose of the IL-17 antibody is 150 mg - 300 mg.

10. The use according to claim 9, wherein the at least one dose of the IL-17 antibody is 150 mg or 300 mg.

11. The use according to any one of claims 8-10, wherein the prior treatment with the IL-17 antibody comprises an induction regimen.

12. The use according to claim 11, wherein the induction regimen comprises a loading regimen.

13. The use according to claim 12, wherein the loading regimen comprises five doses of 150 mg - 300 mg of the IL-17 antibody, each of the five doses adapted for weekly administration to the patient, beginning on week zero.

14. The use according to claim 13, wherein the five doses are each 150 mg or 300 mg.

15. The use according to claim 14, wherein the five doses of 150 mg are indicated for administration to the patient if the patient weighs less than 90 kg and wherein the five doses of 300 mg are indicated for administration to the patient if the patient weighs more than or equal to 90 kg.

16. The use according to claim 14, wherein the induction regimen further comprises a dose of 150 mg - 300 mg of the IL-17 antibody during week eight.

17. The use according to any one of claims 8-16, wherein the prior treatment with the IL-17 antibody comprises at least one dose of the IL-17 antibody at start of relapse.

18. The use according to claim 1, wherein, prior to step a), the patient has not been previously treated with a systemic agent for psoriasis.

19. The use according to claim 1, wherein, prior to step a), the patient has been previously treated with a systemic agent for psoriasis.

20. The use according to claim 19, wherein the systemic agent is selected from the group consisting of methotrexate, cyclosporine, fumaric acid esters, acitretin, alefacept, adalimumab, efalizumab, etanercept, infliximab, golimumab and ustekinumab.

21. Use of an IL-17 antibody in the preparation of a medicament for treating psoriasis, wherein the IL-17 antibody is:

a) adapted for administration to a patient in need thereof during an induction regimen, wherein the induction regimen comprises a loading regimen that provides a mean maximum plasma concentration (C_{max}) of the IL-17 antibody of 52 µg/ml - 104 µg/ml; and

b) thereafter, adapted for administration to the patient during a maintenance regimen that provides an average steady-state trough level of the IL-17 antibody between 5 µg/ml - 70 µg/ml, wherein said IL-17 antibody binds to an epitope of an IL-17 homodimer having two mature IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain, wherein the IL-17 antibody has a K_D of 100-200 pM, and wherein the IL-17 antibody has an *in vivo* half-life of 23-30 days.

22. The use of claim 21, wherein the loading regimen provides a C_{max} of the IL-17 antibody of 52 µg/ml at day 32.

23. The use of claim 21, wherein the maintenance regimen provides an average steady-state trough level of the IL-17 antibody of 5 µg/ml – 33 µg/ml.

24. The use of claim 23, wherein the maintenance regimen provides an average steady-state trough level of the IL-17 antibody of 16 µg/ml.

25. The use of claim 21, wherein the loading regimen provides a C_{max} of the IL-17 antibody of 104 μg/ml at day 32.

26. The use of claim 21, wherein the maintenance regimen provides an average steady-state trough level of the IL-17 antibody of 11 μg/ml – 70 μg/ml.

27. The use of claim 26, wherein the maintenance regimen provides an average steady-state trough level of the IL-17 antibody of 33 μg/ml.

28. The use of claim 21, wherein the induction regimen is twelve weeks.

29. The use of claim 21, wherein the maintenance regimen employs monthly dosing of the IL-17 antibody.

30. Use of an IL-17 antibody in the preparation of a medicament for treating psoriasis, wherein the IL-17 antibody is:

a) adapted for administration to a patient in need thereof during an induction regimen, wherein the induction regimen comprises a loading regimen that provides a mean trough level one month after the fourth dose of 29.2 μg/ml; and

b) thereafter, adapted for administration to the patient during a maintenance regimen that provides an average steady-state trough level of the IL-17 antibody of 15 μg/ml, wherein said IL-17 antibody binds to an epitope of an IL-17 homodimer having two mature IL-17 protein chains, said epitope comprising Leu74, Tyr85, His86, Met87, Asn88, Val124, Thr125, Pro126, Ile127, Val128, His129 on one chain and Tyr43, Tyr44, Arg46, Ala79, Asp80 on the other chain, wherein the IL-17 antibody has a K_D of 100-200 pM, and wherein the IL-17 antibody has an *in vivo* half-life of 23-30 days.

31. The use according to any one of the above claims, wherein the IL-17 antibody comprises:

a) an immunoglobulin V_H domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin V_L domain comprising the amino acid sequence set forth as SEQ ID NO:10;

b) an immunoglobulin V_H domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin V_L domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; or

c) an immunoglobulin V_H domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin V_L domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.

32. The use according to any of claims 6-17, wherein start of relapse is defined as the loss of 20% of the maximum PASI response achieved at any time before the visit at which the assessment of start or relapse is made and loss of PASI75.

33. The use according to any of the above claims, wherein the psoriasis is chronic plaque-type psoriasis.

34. Use of an IL-17 antibody in the preparation of a medicament for treating psoriasis, wherein the IL-17 antibody is:

a) adapted for administration to a patient in need thereof as five doses of 150 mg - 300 mg, each of the five doses being delivered weekly; and

b) thereafter, adapted for administration to the patient as a monthly dose of 150 mg - 300 mg, wherein the IL-17 antibody comprises:

i) an immunoglobulin V_H domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin V_L domain comprising the amino acid sequence set forth as SEQ ID NO:10;

ii) an immunoglobulin V_H domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin V_L domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; or

iii) an immunoglobulin V_H domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin V_L domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.

35. Use of an IL-17 antibody in the preparation of a medicament for treating psoriasis, wherein the IL-17 antibody is:

a) adapted for administration to a patient in need thereof as five doses of 150 mg - 300 mg, each of the five doses being delivered weekly; and

b) thereafter, adapted for administration to the patient as at least one dose of 150 mg - 300 mg at start of relapse, wherein the IL-17 antibody comprises:

i) an immunoglobulin V_H domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin V_L domain comprising the amino acid sequence set forth as SEQ ID NO:10;

ii) an immunoglobulin V_H domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin V_L domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; or

iii) an immunoglobulin V_H domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin V_L domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.

36. The use according to claim 34, wherein the medicament is adapted for administration of 150 mg - 300 mg doses of the IL-17 antibody during weeks 0, 1, 2, 3, 4, and 8, and then monthly thereafter.


37. The use according to any one of claims 34-36, wherein all doses according to step a) and all doses according to step b) are 300 mg.

38. The use according to claim 35, wherein start of relapse is defined as the loss of 20% of the maximum PASI response achieved at any time before the visit at which the assessment of start or relapse is made and loss of PASI75.

39. The use according to any of the above claims, wherein the psoriasis is moderate to severe chronic plaque-type psoriasis.

40. The use according to any of the above claims, wherein the IL-17 antibody is adapted for subcutaneous delivery.

41. The use according to any of the above claims, wherein the IL-17 antibody is secukinumab.



WHAT IS CLAIMED IS:

1. Use of an IL-17 antibody in the preparation of a medicament for treating psoriasis, wherein the IL-17 antibody is:

a) adapted for administration to a patient in need thereof during an induction regimen, wherein the induction regimen comprises a loading regimen, wherein the loading regimen comprises five doses of 150 mg - 300 mg of the IL-17 antibody, each of the five doses adapted for delivery weekly, beginning on week zero; and

b) thereafter, adapted for administration to the patient during a maintenance regimen, wherein said IL-17 antibody comprises:

i) an immunoglobulin V_H domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin V_L domain comprising the amino acid sequence set forth as SEQ ID NO:10;

ii) an immunoglobulin V_H domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin V_L domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; or

iii) an immunoglobulin V_H domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin V_L domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.

2. The use according to claim 1, wherein the loading regimen comprises five doses of 150 mg or 300 mg of the IL-17 antibody.

3. The use according to claim 2, wherein the five doses of 150 mg are indicated for administration to the patient if the patient weighs less than 90 kg and wherein the five doses of 300 mg are indicated for administration to the patient if the patient weighs more than or equal to 90 kg.

4. The use according to claim 3, wherein the induction regimen further comprises a dose of 150 mg - 300 mg of the IL-17 antibody during week eight.

5. The use according to any one of claims 1-4, wherein the maintenance regimen comprises a monthly dose of 150 mg - 300 mg of the IL-17 antibody.

6. The use according to any one of claims 1-4, wherein the maintenance regimen comprises at least one dose of 150 mg - 300 mg of the IL-17 antibody at start of relapse.

7. The use according to claim 6, wherein the maintenance regimen further comprises at least one dose of 150 mg - 300 mg of the IL-17 antibody at each additional start of relapse.

8. Use of an IL-17 antibody in the preparation of a medicament for treating psoriasis, wherein at least one dose of the IL-17 antibody is adapted for administration to a patient in need thereof at start of relapse from a prior treatment with the IL-17 antibody, wherein said IL-17 antibody comprises:

a) an immunoglobulin V_H domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin V_L domain comprising the amino acid sequence set forth as SEQ ID NO:10;

b) an immunoglobulin V_H domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin V_L domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; or

c) an immunoglobulin V_H domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin V_L domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.

9. The use according to claim 8, wherein the at least one dose of the IL-17 antibody is 150 mg - 300 mg.

10. The use according to claim 9, wherein the at least one dose of the IL-17 antibody is 150 mg or 300 mg.

11. The use according to any one of claims 8-10, wherein the prior treatment with the IL-17 antibody comprises an induction regimen.

12. The use according to claim 11, wherein the induction regimen comprises a loading regimen.

13. The use according to claim 12, wherein the loading regimen comprises five doses of 150 mg - 300 mg of the IL-17 antibody, each of the five doses adapted for weekly administration to the patient, beginning on week zero.

14. The use according to claim 13, wherein the five doses are each 150 mg or 300 mg.

15. The use according to claim 14, wherein the five doses of 150 mg are indicated for administration to the patient if the patient weighs less than 90 kg and wherein the five doses of 300 mg are indicated for administration to the patient if the patient weighs more than or equal to 90 kg.

16. The use according to claim 14, wherein the induction regimen further comprises a dose of 150 mg - 300 mg of the IL-17 antibody during week eight.

17. The use according to any one of claims 8-16, wherein the prior treatment with the IL-17 antibody comprises at least one dose of the IL-17 antibody at start of relapse.

18. The use according to claim 1, wherein, prior to step a), the patient has not been previously treated with a systemic agent for psoriasis.

19. The use according to claim 1, wherein, prior to step a), the patient has been previously treated with a systemic agent for psoriasis.

20. The use according to claim 19, wherein the systemic agent is selected from the group consisting of methotrexate, cyclosporine, fumaric acid esters, acitretin, alefacept, adalimumab, efalizumab, etanercept, infliximab, golimumab and ustekinumab.

21. The use according to any of claims 6-17, wherein start of relapse is defined as the loss of 20% of the maximum PASI response achieved at any time before the visit at which the assessment of start or relapse is made and loss of PASI75.

22. The use according to any of the above claims, wherein the psoriasis is chronic plaque-type psoriasis.

23. Use of an IL-17 antibody in the preparation of a medicament for treating psoriasis, wherein the IL-17 antibody is:

a) adapted for administration to a patient in need thereof as five doses of 150 mg - 300 mg, each of the five doses being delivered weekly; and

b) thereafter, adapted for administration to the patient as a monthly dose of 150 mg - 300 mg, wherein the IL-17 antibody comprises:

i) an immunoglobulin V_H domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin V_L domain comprising the amino acid sequence set forth as SEQ ID NO:10;

ii) an immunoglobulin V_H domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin V_L domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; or

iii) an immunoglobulin V_H domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin V_L domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.

24. Use of an IL-17 antibody in the preparation of a medicament for treating psoriasis, wherein the IL-17 antibody is:

a) adapted for administration to a patient in need thereof as five doses of 150 mg - 300 mg, each of the five doses being delivered weekly; and

b) thereafter, adapted for administration to the patient as at least one dose of 150 mg - 300 mg at start of relapse, wherein the IL-17 antibody comprises:

i) an immunoglobulin V_H domain comprising the amino acid sequence set forth as SEQ ID NO:8 and an immunoglobulin V_L domain comprising the amino acid sequence set forth as SEQ ID NO:10;

ii) an immunoglobulin V_H domain comprising the hypervariable regions set forth as SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 and an immunoglobulin V_L domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6; or

iii) an immunoglobulin V_H domain comprising the hypervariable regions set forth as SEQ ID NO:11, SEQ ID NO:12 and SEQ ID NO:13 and an immunoglobulin V_L domain comprising the hypervariable regions set forth as SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6.

25. The use according to claim 34, wherein the medicament is adapted for administration of 150 mg - 300 mg doses of the IL-17 antibody during weeks 0, 1, 2, 3, 4, and 8, and then monthly thereafter.

26. The use according to any one of claims 34-36, wherein all doses according to step a) and all doses according to step b) are 300 mg.

27. The use according to claim 35, wherein start of relapse is defined as the loss of 20% of the maximum PASI response achieved at any time before the visit at which the assessment of start or relapse is made and loss of PASI75.

28. The use according to any of the above claims, wherein the psoriasis is moderate to severe chronic plaque-type psoriasis.

29. The use according to any of the above claims, wherein the IL-17 antibody is adapted for subcutaneous delivery.

30. The use according to any of the above claims, wherein the IL-17 antibody is secukinumab.

31. Use of 150 mg secukinumab in the manufacture of a medicament for the treatment of moderate to severe plaque psoriasis, wherein the medicament is for subcutaneous injection to a patient in need thereof at weeks 0, 1, 2 and 3, followed by once monthly dosing starting at week 4.

32. Use of 300 mg secukinumab in the manufacture of a medicament for the treatment of moderate to severe plaque psoriasis, wherein the medicament is for subcutaneous injection to a patient in need thereof at weeks 0, 1, 2 and 3, followed by once monthly dosing starting at week 4.